GlassScriptPhysician profile
Mason M Fish
NPI 1598342610
$16,166.88
in general payments reported to CMS, 2019-2025
30 companies · $4,345 in 2025
The $4,345 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $3,656 · 2023: $3,575 · 2024: $3,306 · 2025: $4,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,125.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,676.58 | 2021-2025 | |
| Axsome Therapeutics, INC. | $2,119.96 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,767.45 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,678.54 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,633.51 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,254.90 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $1,211.35 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $677.11 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $594.69 | 2021-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $370.78 | 2024-2025 | Cobenfy |
| Corium, LLC | $360.57 | 2022-2025 | Azstarys |
| Lundbeck LLC | $272.80 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $257.12 | 2023-2025 | Trintellix |
| Bausch Health US, LLC | $228.15 | 2022-2025 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $170.99 | 2025 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $149.94 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $96.51 | 2024-2025 | Xelstrym |
| Biogen, INC. | $95.00 | 2023 | |
| Novo Nordisk INC | $79.99 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Almatica Pharma LLC | $63.90 | 2023-2025 | Loreev Xr, Gralise, Teriparatide |
| Harmony Biosciences LLC | $60.19 | 2024 | |
| Sage Therapeutics, LLC | $59.38 | 2022-2025 | Zurzuvae |
| Indivior INC. | $53.25 | 2022 | |
| Supernus Pharmaceuticals, INC. | $50.62 | 2023-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $49.71 | 2024 | |
| Tms Neurohealth Centers INC. | $47.18 | 2025 | Tms Neurohealth Centers INC. |
| Tris Pharma INC | $24.02 | 2024 | Dyanavel Xr |
| Alfasigma USA, INC. | $22.70 | 2021 | |
| Validus Pharmaceuticals LLC | $21.33 | 2024 | Equetro |
| Neos Therapeutics, LP | $18.66 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.